• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亨廷顿病运动表现的医学管理

Medical management of motor manifestations of Huntington disease.

作者信息

McCusker Elizabeth A, Loy Clement T

机构信息

Huntington Disease Service, Westmead Hospital, Westmead, Australia.

Huntington Disease Service, Westmead Hospital, Westmead, Australia; School of Public Health, University of Sydney, Sydney, Australia.

出版信息

Handb Clin Neurol. 2017;144:141-150. doi: 10.1016/B978-0-12-801893-4.00012-2.

DOI:10.1016/B978-0-12-801893-4.00012-2
PMID:28947112
Abstract

The motor and movement disorders of Huntington disease (HD) are managed in the context of the other disease features. Chorea and dystonia are the most common HD-associated movement disorders, and they can be assessed on research rating scales. However other motor manifestations have a significant impact. In particular, dysphagia influences choice and tolerance of treatment for the movement disorder, as will comorbidities, patient awareness, and distress related to the motor feature or movement. Treatment for other disease features may aggravate the motor disorder, e.g., increased swallowing difficulty associated with antipsychotic agents. Basic principles in deciding to institute a treatment are outlined as well as treatment of specific motor manifestations and movements. There is a paucity of evidence to support the treatments available for the motor disorder, with only one agent with class 1 evidence, tetrabenazine, for chorea. There are, however, treatments informed by expert opinion which reflect the management of a wider HD phenotype than that represented in clinical trials. Some treatments are based on evidence from use in other conditions. Medical management is usually undertaken later in the disease with concurrent nonmedical interventions after multidisciplinary assessments. Medication review with HD progression is essential.

摘要

亨廷顿舞蹈症(HD)的运动和运动障碍是在其他疾病特征的背景下进行管理的。舞蹈症和肌张力障碍是与HD相关的最常见运动障碍,可通过研究评分量表进行评估。然而,其他运动表现也有重大影响。特别是吞咽困难会影响运动障碍治疗的选择和耐受性,合并症、患者意识以及与运动特征或运动相关的痛苦也会产生影响。其他疾病特征的治疗可能会加重运动障碍,例如,抗精神病药物会增加吞咽困难。本文概述了决定进行治疗的基本原则以及特定运动表现和运动的治疗方法。支持现有运动障碍治疗方法的证据很少,只有一种具有1类证据的药物——丁苯那嗪可用于治疗舞蹈症。然而,有一些基于专家意见的治疗方法,这些方法反映了比临床试验中所代表的更广泛的HD表型的管理。一些治疗方法是基于在其他病症中的使用证据。疾病后期通常在多学科评估后同时进行非药物干预的情况下进行药物治疗。随着HD病情进展进行药物审查至关重要。

相似文献

1
Medical management of motor manifestations of Huntington disease.亨廷顿病运动表现的医学管理
Handb Clin Neurol. 2017;144:141-150. doi: 10.1016/B978-0-12-801893-4.00012-2.
2
Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.泰必利嗪治疗运动障碍:文献综述。
Clin Ther. 2012 Jul;34(7):1487-504. doi: 10.1016/j.clinthera.2012.06.010. Epub 2012 Jun 28.
3
Tetrabenazine and movement disorders.
Neurology. 1981 Aug;31(8):1051-4. doi: 10.1212/wnl.31.8.1051.
4
Dystonia-predominant adult-onset Huntington disease: association between motor phenotype and age of onset in adults.以肌张力障碍为主的成人起病型亨廷顿病:成人运动表型与发病年龄之间的关联
Arch Neurol. 2000 Sep;57(9):1326-30. doi: 10.1001/archneur.57.9.1326.
5
Huntington's disease: present treatments and future therapeutic modalities.
Int Clin Psychopharmacol. 2004 Mar;19(2):51-62. doi: 10.1097/00004850-200403000-00001.
6
Is non-recognition of choreic movements in Huntington disease always pathological?亨廷顿舞蹈病中舞蹈样动作不自知是否总是病理性的?
Neuropsychologia. 2013 Mar;51(4):748-59. doi: 10.1016/j.neuropsychologia.2012.12.005. Epub 2012 Dec 21.
7
State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.用于减少亨廷顿舞蹈病舞蹈症状的最先进药理学方法。
Expert Opin Pharmacother. 2021 Jun;22(8):1015-1024. doi: 10.1080/14656566.2021.1876666. Epub 2021 Feb 8.
8
New symptomatic therapies for Huntington disease.亨廷顿舞蹈症的新对症疗法。
Handb Clin Neurol. 2017;144:199-207. doi: 10.1016/B978-0-12-801893-4.00017-1.
9
Involuntary movement disorders.运动障碍性疾病
Neurol Clin. 1984 Feb;2(1):71-89.
10
Pharmacologic approaches to the treatment of Huntington's disease.治疗亨廷顿病的药物治疗方法。
Mov Disord. 2012 Jan;27(1):31-41. doi: 10.1002/mds.23953. Epub 2011 Oct 13.

引用本文的文献

1
Divergent Effects of the Nonselective Adenosine Receptor Antagonist Caffeine in Pre-Manifest and Motor-Manifest Huntington's Disease.非选择性腺苷受体拮抗剂咖啡因在临床前和运动性亨廷顿病中的不同作用
Biomedicines. 2022 May 27;10(6):1258. doi: 10.3390/biomedicines10061258.